BIO - Bio-Rad Laboratories, Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $2.79
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$327.50
DETAILS
HIGH:
$335.00
LOW:
$320.00
MEDIAN:
$327.50
CONSENSUS:
$327.50
UPSIDE:
21.88%
Market Cap:
7.25B
Volume:
241,443
Avg Volume:
228,400
52 Week Range:
211.43-343.12
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
1.18
Last Dividend:
$N/A
Exchange:
NYSE
Country:
US
Employees:
7,700
IPO Date:
1980-02-27
EPS (TTM):
27.87
P/E Ratio:
10.87
Revenue (TTM):
2.58B
Total Assets:
10.58B
Total Debt:
1.53B
Cash & Equiv:
531.80M
Rev Growth (5Y):
0.3%
EPS Growth (5Y):
-26.3%
FCF Growth (5Y):
-4.7%
ROCE:
2.7%
Debt/Equity:
0.21
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $2.51 | $2.57 | -2.3% | $693.2M | $599.7M | +15.6% |
| 2025-10-29 | $2.26 | $2.30 | -1.7% | $653.0M | $694.6M | -6.0% |
| 2025-07-31 | $2.61 | $1.93 | +35.2% | $651.6M | $633.8M | +2.8% |
| 2025-05-01 | $2.54 | $1.73 | +46.8% | $585.4M | $573.2M | +2.1% |
| 2025-02-13 | $2.90 | $2.86 | +1.4% | $667.5M | $679.8M | -1.8% |
| 2024-10-30 | $2.01 | $1.28 | +57.0% | $649.7M | $681.3M | -4.6% |
| 2024-08-01 | $3.11 | $2.12 | +46.7% | $638.5M | $645.8M | -1.1% |
| 2024-05-07 | $2.29 | $2.15 | +6.5% | $610.8M | $619.1M | -1.3% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.58B | 2.57B | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B | 2.02B | 2.18B |
| Net Income | 759.90M | (1.84B) | (637.32M) | (3.63B) | 4.25B | 3.81B | 1.76B | 361.00M | 114.74M | 28.12M | 113.09M | 88.84M |
| EPS | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 | 127.86 | 58.93 | 12.10 | 4.12 | 0.88 | 3.74 | 3.08 |
| Total Assets | 10.58B | 9.36B | 12.30B | 13.50B | 17.80B | 12.97B | 8.01B | 5.61B | 4.27B | 3.85B | 3.71B | 3.34B |
| Total Debt | 1.53B | 1.37B | 1.41B | 1.39B | 223.38M | 225.74M | 651.18M | 439.43M | 435.00M | 434.52M | 434.18M | 435.98M |
| Cash & Equivalents | 531.80M | 488.10M | 403.80M | 434.21M | 470.78M | 662.21M | 660.67M | 431.53M | 383.82M | 456.26M | 457.55M | 413.25M |
| Operating Cash Flow | 532.20M | 455.20M | 374.94M | 194.45M | 669.46M | 584.97M | 457.90M | 285.49M | 104.14M | 216.07M | 186.21M | 273.31M |
| Free Cash Flow | 374.60M | 266.20M | 218.26M | 80.29M | 535.72M | 476.41M | 359.37M | 155.67M | (10.99M) | 74.50M | 72.84M | 136.83M |
| FCF per Share | 13.74 | 9.44 | 7.47 | 2.70 | 17.96 | 16.00 | 12.04 | 5.22 | -0.37 | 2.53 | 2.50 | 4.74 |
| Book Value | 7.45B | 6.57B | 8.74B | 9.62B | 13.69B | 9.88B | 5.76B | 4.02B | 2.93B | 2.58B | 2.49B | 2.19B |
| Cash & ST Investments | 1.54B | 1.66B | 1.61B | 1.79B | 869.92M | 991.12M | 1.11B | 844.80M | 754.98M | 839.44M | 786.27M | 697.63M |
| ROC Equity | 0.10 | -0.28 | -0.07 | -0.38 | 0.31 | 0.39 | 0.31 | 0.09 | 0.04 | 0.01 | 0.05 | 0.04 |